【摘 要】
：
Objective: The purpose of this investigation was to clarify the spread conditions of Fluoride Mouth Rinsing Programme (S-FMR) throughout Japan.Subjects and Methods: The latest survey, the third joint
【机 构】
：
Department of Oral Health, Graduate School of Dentistry, Kanagawa Dental University, Japan
【出 处】
：
The 11th International Conference of Asian Academy of Preven
论文部分内容阅读
Objective: The purpose of this investigation was to clarify the spread conditions of Fluoride Mouth Rinsing Programme (S-FMR) throughout Japan.Subjects and Methods: The latest survey, the third joint with 8020 Promotion Foundation, WHO Collaborating Center for Translation of Oral Health Science and NPO-JPUF, was conducted in 2012.Questionnaires were sent to manager of oral health in all 47 prefectures having own public health centers (recovery rate 100％).
其他文献
促进护理进展的因素护理专业自身发展的需要护理对象范围扩大及其需求的增加医疗技术的进步及治疗模式的变化国家政策的要求放疗护理进展的体现生活质量研究仍受关注症状管理的研究进展连续护理模式的开展
特点1.在质子治疗相关报道12篇,占比重较大;治疗的疗效与副反应质子治疗与光子治疗的比较2.2013年的术中放疗,本次无报道;3.质子治疗涉及到髓母细胞瘤3篇,颅咽管瘤2篇,中枢神经系统肿瘤5篇,鼻咽癌1篇,视网膜母细胞瘤1篇
输尿管癌术后复发前列腺癌治疗模式转变?巴菲特致信股东称患前列腺癌2012年7月接受放疗Utilization from 2002-2005放射治疗在肿瘤治疗中地位日本10年前列腺癌放射性粒子治疗肿瘤治疗基本原则与实践
内容·EAU前列腺癌放疗指南解读-EAU、ESTRO与NCCN、AUA、AETRO比较·欧洲前列腺癌放疗靶区勾画指南解读-ESTRO根治性放疗靶区勾画指南-ESRTO术后放疗靶区勾画指南·2014年前列腺癌放疗新进展
·早期非小细胞肺癌SBRT的放疗剂量·局部晚期非小细胞肺癌的放疗剂量· 日本Onishi早期研究(241例Ⅰ期NSCLC)提高立体定向放射治疗(SBRT)剂量可以提高病人生存率可手术病人放疗BED＞100Gy和＜100Gy的3年OS分别为88.4％和69.4％(P＜0.01)· ASTR0 2013: SBRT治疗Ⅰ期NSCLC—多中心临床结果-2000多例病;放疗剂量:32-70Gy/3-12f
讲课提纲胃癌术后放疗之我见胃癌术后到底需不需要放疗胃癌治疗个体化趋势?胃癌放疗靶区勾画规范2014 ASTRO胃癌进展胃癌根治术后需要放疗吗?D0-1VSD2术者的水平我国的情况
食管癌综合治疗具体结合模式——Meta分析与Ⅲ期临床结合2014 NCCN指南术前新辅助放化疗术后辅助治疗价值根治性放化疗结果与问题新辅助治疗的临床价值——Meta分析的新结果Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated me
OC: Oral Communication: 14 PO&PD: Posters&Poster Discuusion: 10 SP:Symposium: 2 Teaching Lecture: 1 术前CRT之后的疗效评价直肠癌近距离治疗的探索Fluorouracil Capecitabine Oxaliplatin, Irinotecan Bevacizumab, Cetuximab
AS far back as the early 80s, Dr Charles Mérieux dreamed of founding a CDC in France, like the one in Atlanta.He wanted it to be near his Institute (Lyon), his Foundation (Annecy), the WHO, and to be
SUPPORTING PROJECTClinical TriaPre-clinical TrialBaSic ResearchBiobank Infrastructure ConstructionDiagnostic TrialAnti-Hr2(Herceptin)in Gastric Cancer ToGA TrialANTI-EGFR(ERBITUX) IN COLORECTAL CANCER